Celldex Therapeutics IncNASDAQ:CLDX
- LAST PRICE38.6800
- TODAY'S CHANGE (%)-0.3100 (-0.7951%)
- Bid / Lots38.6600/ 4
- Ask / Lots38.7700/ 4
- Open / Previous Close38.8400 / 38.9900
- Day Range
- 52 Week Range
- Volume85,357
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CLDX |
|---|---|---|
| 09:32 ET | 3834 | 39.01 |
| 09:34 ET | 1595 | 38.72 |
| 09:36 ET | 300 | 38.84 |
| 09:38 ET | 100 | 38.67 |
| 09:39 ET | 900 | 38.915 |
| 09:45 ET | 609 | 38.945 |
| 09:50 ET | 498 | 38.86 |
| 09:52 ET | 200 | 38.965 |
| 09:54 ET | 200 | 38.95 |
| 09:56 ET | 3874 | 39.1 |
| 09:59 ET | 600 | 39.07 |
| 10:01 ET | 1136 | 39.04 |
| 10:03 ET | 400 | 39.03 |
| 10:08 ET | 100 | 39.02 |
| 10:10 ET | 4552 | 38.955 |
| 10:12 ET | 2356 | 38.93 |
| 10:14 ET | 9729 | 38.51 |
| 10:15 ET | 1265 | 38.57 |
| 10:21 ET | 600 | 38.44 |
| 10:24 ET | 100 | 38.53 |
| 10:26 ET | 100 | 38.54 |
| 10:28 ET | 4300 | 38.6 |
| 10:30 ET | 200 | 38.66 |
| 10:32 ET | 200 | 38.655 |
| 10:33 ET | 2144 | 38.595 |
| 10:35 ET | 300 | 38.54 |
| 10:37 ET | 300 | 38.54 |
| 10:39 ET | 2400 | 38.54 |
| 10:42 ET | 600 | 38.545 |
| 10:44 ET | 100 | 38.47 |
| 10:46 ET | 2700 | 38.22 |
| 10:48 ET | 300 | 38.295 |
| 10:50 ET | 628 | 38.26 |
| 10:51 ET | 1000 | 38.38 |
| 10:53 ET | 300 | 38.315 |
| 10:55 ET | 600 | 38.39 |
| 11:00 ET | 300 | 38.54 |
| 11:02 ET | 200 | 38.575 |
| 11:04 ET | 600 | 38.605 |
| 11:06 ET | 553 | 38.59 |
| 11:08 ET | 400 | 38.59 |
| 11:09 ET | 1300 | 38.59 |
| 11:11 ET | 2181 | 38.585 |
| 11:13 ET | 500 | 38.62 |
| 11:18 ET | 1100 | 38.575 |
| 11:20 ET | 100 | 38.53 |
| 11:24 ET | 435 | 38.57 |
| 11:26 ET | 2584 | 38.62 |
| 11:27 ET | 300 | 38.68 |
Jun 18, 2024
DJ Celldex Therapeutics Price Target Maintained With a $67.00/Share by Cantor Fitzgerald, from 9:54AM ET on Tuesday Jun 18, 2024 by Dow Jones
9:54AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 4, 2024
Celldex Therapeutics to Present at Jefferies Healthcare Conference, from 4:01PM ET on Tuesday Jun 04, 2024 by Dow Jones
4:01PM ET on Tuesday Jun 04, 2024 by Dow Jones
Jun 3, 2024
DJ Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 7:24AM ET on Monday Jun 03, 2024 by Dow Jones
7:24AM ET on Monday Jun 03, 2024 by Dow Jones
Jun 2, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Celldex Therapeutics Inc | 2.6B | -13.6x | --- |
Geron Corp | 2.6B | -12.2x | --- |
MoonLake Immunotherapeutics | 2.7B | -55.6x | --- |
Agios Pharmaceuticals Inc | 2.5B | -6.8x | --- |
IDEAYA Biosciences Inc | 2.7B | -17.4x | --- |
SpringWorks Therapeutics Inc | 2.9B | -7.3x | --- |
Company Information
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Contact Information
- Headquarters
- 53 Frontage Road, Suite 220HAMPTON, NJ, United States 08827
- Phone
- 908-200-7500
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Karen Shoos
- President, Chief Executive Officer, Director
- Anthony Marucci
- Chief Financial Office, Senior Vice President, Secretary
- Sam Martin
- Executive Vice President, Chief Scientific Officer
- Tibor Keler
- Senior Vice President, General Counsel
- Freddy Jimenez
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
|---|---|
Revenue (TTM) | $6.1M |
Shares Outstanding | 65.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.58 |
EPS | $-2.84 |
Book Value | $7.68 |
P/E Ratio | -13.6x |
Price/Sales (TTM) | 423.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,679.17% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
